paxlovid

  1. SNT Gatchaman

    Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA PAX LC, 2025, Sawano, Iwasaki+

    Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA PAX LC: a double-blind, randomised, placebo-controlled, phase 2, decentralised trial Mitsuaki Sawano; Bornali Bhattacharjee; César Caraballo; Rohan Khera; Shu-Xia Li; Jeph Herrin; Dany Christian; Andreas...
  2. forestglip

    Risk of [LC] and Oral Antivirals in Adults Aged Over 60 years: A Nationwide Retrospective Cohort Study, 2025, Jooa et al

    Risk of Post-Acute Sequelae of COVID-19 and Oral Antivirals in Adults Aged Over 60 years: A Nationwide Retrospective Cohort Study Hyejin Jooa, Eunji Kimc, Kyungmin Huhd, Gi Hwan Baea, Hyungmin Leee, Jungyeon Kime, Dong-Hwi Kime, Min-Gyu Yooe, Il Uk Joi, Poong Hoon Leei, Geun Woo Leei, Hee Sun...
  3. forestglip

    Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir, 2025, Mafi et al

    Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir John N. Mafi, Sitaram Vangala, Moira K. Kapral, Peter E. Wu, Manying Cui, Artem Romanov, Katherine L. Kahn Abstract Randomized clinical trials of nirmatrelvir-ritonavir found reduced...
  4. forestglip

    Preprint Anticoagulant vs. antiviral therapy, recovery and neurodamage in Long COVID: a real-world prospective cohort study, 2025, Jamoulle et al

    Anticoagulant vs. antiviral therapy, recovery and neurodamage in Long COVID: a real-world prospective cohort study Marc Jamoulle, Margaux Mignolet, Isabelle Meyts, Aurelie Ladang, Charles Nicaise, Johan Van Weyenbergh [Line breaks added] Abstract Recent estimates consider that Long COVID...
  5. SNT Gatchaman

    Preprint Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients – [...] RECOVER, 2024, Wang et al.

    Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients – A Large-Scale Observational Cohort Study from the RECOVER Initiative Fei Wang; Chengxi Zang; Haoyang Li; Dhru Khullar; Yongkang Zhang; Stephenson Strobel; Yong Chen; Marc Sala; Payal Patel...
  6. SNT Gatchaman

    Preprint Effect of Paxlovid Treatment on Long COVID Onset: An EHR-Based Target Trial Emulation from N3C, 2024, Preiss et al.

    Effect of Paxlovid Treatment on Long COVID Onset: An EHR-Based Target Trial Emulation from N3C Alexander Preiss; Abhishek Bhatia; Chengxi Zang; Leyna V Aragon; John M Baratta; Monika Baskaran; Frank Blancero; M Daniel Brannock; Robert F Chew; Ivan Diaz; Megan Fitzgerald; Elizabeth P Kelly...
  7. John Mac

    Study Reveals Paxlovid Does Little to Stave Off Long COVID

    The study reveals a higher-than-previously-reported number of patients experienced a rebound after Paxlovid treatment, challenging previous assumptions. Despite receiving Paxlovid, individuals with long COVID exhibited similar symptoms to those who didn’t receive the treatment. However, the...
  8. E

    Nirmatrelvir/ritonavir and risk of long COVID symptoms: A retrospective cohort study, 2023, Congdon et al

    Nirmatrelvir/ritonavir and risk of long COVID symptoms: A retrospective cohort study We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were...
  9. Kalliope

    Protocol Paxlovid for Treatment of Long Covid (STOP-PASC), 2022, Singh et al, Stanford University - recruitment stopped June 2023

    Medpage Today Stanford Study of Paxlovid for Long COVID Stopped Early Quote: Two sources familiar with the STOP-PASC study told MedPage Today that trial enrollment had been halted. One was told by a study coordinator that a preliminary review found "inconclusive evidence" for the primary...
  10. mango

    Open Sweden: imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC) 2023 Brodin et al

    imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC) https://clinicaltrials.gov/ct2/show/NCT05823896 Petter Brodin Karolinska Institutet, Sweden "Brief Summary: The purpose of this study is to investigate the efficacy of orally administered nirmatrelvir/ritonavir compared with...
  11. Mij

    Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition, 2023, Yan Xie, PhD et al

    Key Points Question Is treatment with nirmatrelvir in the acute phase of SARS-CoV-2 infection associated with a lower risk of post–COVID-19 condition (PCC)? Findings In this cohort study of 281 793 people with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe...
  12. LarsSG

    [Preprint] Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19, 2022, Al-Aly et al

    Abstract: Long Covid -- the disease encompassing the post-acute sequelae of SARS-CoV-2 (PASC) -- affects millions of people around the world. Prevention of PASC is an urgent public health priority. In this work, we aimed to examine whether treatment with nirmatrelvir in the acute phase of...
  13. RedFox

    Protocol RECOVER Treatment Study: Paxlovid for long Covid

    The RECOVER Initiative is doing a trial on Paxlovid for long Covid. Here's the listing on ClinicalTrials.gov: SARS CoV-2 Viral Persistence Study (PASC) - Study of Long COVID-19 (PASC) Highlights: Double-blind multi-center trial in the US 1700 participants They'll take the drug for 15 days...
  14. Lidia Thompson

    Antivirals as ME/CFS or Long Covid treatments (e.g. valacyclovir, valgancyclovir, amantadine)

    Split from Mail Online: Why many of those struck by Long Covid may be suffering from glandular fever: Blood tests on some patients are coming back positive for ‘ Here is a link from ME-pedia on the use use of valaciclovir. The study that is mentioned on this page showed that, " Improvement...
Back
Top Bottom